Samsung's June 2026 Samsung Health update introduces Vitals, Heart Health Score, Daily Cardio Load, and Fitness Index, analyzing five overnight bio-signals ahead of a new Galaxy Watch unveiled July 22.
Oura's Ring 5, shipping June 4, 2026, is 40 percent smaller and adds AI-driven Health Radar blood-pressure monitoring, GLP-1 Insights, and AI meal-tracking features starting at $399.
Whoop's May 2026 update adds AI features called My Memory and Proactive Check-Ins, plus on-demand clinician video consultations and electronic health record syncing for members.
A new study presented at the 2026 International Stroke Conference found Viz.ai's platform cut door-in-door-out transfer time for large vessel occlusion stroke patients by 44% at a regional Adventist Health + Rideout hospital, reducing care-team notification time from 45 minutes to 7.
Cellens, a Boston cancer diagnostics startup, raised a $6.5M Series Seed round led by SOSV for its AI and atomic-force-microscopy-based BioFeel test, which identified every recurrence case in a nearly 100-patient study versus 60-65% sensitivity for standard molecular assays.
Helsinki-based Aiforia secured €20 million in milestone-gated venture debt financing from the European Investment Bank to expand its deep-learning platform for AI-assisted cancer detection in digital pathology.
Owkin announced on June 5, 2026 a multi-year expansion of its Sanofi partnership, licensing its K Pro 'AI Scientist' platform for five years to build autonomous AI agents that independently carry out pharmaceutical research tasks.
Eli Lilly has launched LillyPod, a 1,016-GPU NVIDIA Blackwell Ultra supercomputer delivering over 9,000 petaflops, which the company describes as the largest AI system owned outright by a pharmaceutical company, to accelerate drug discovery and genomics research.
Aidoc won FDA clearance in January 2026 for a foundation-model AI workflow that triages 14 acute conditions from a single abdominal CT scan, hitting 97% mean sensitivity and 98% mean specificity in its pivotal study.
Insilico Medicine and Bora Pharmaceuticals announced a strategic alliance on July 14, 2026 worth up to $2.5 billion, aiming to extend Insilico's generative AI platform Pharma.AI from drug discovery into pharmaceutical manufacturing and quality operations.